Holen Sie sich die Stockscreener-App
6.80
3.66%
0.24
Handel nachbörslich:
6.91
0.11
+1.62%
Schlusskurs vom Vortag:
$6.56
Offen:
$6.72
24-Stunden-Volumen:
500.89K
Relative Volume:
1.15
Marktkapitalisierung:
$127.58M
Einnahmen:
$109.43M
Nettoeinkommen (Verlust:
$5.13M
KGV:
26.09
EPS:
0.2606
Netto-Cashflow:
$18.91M
1W Leistung:
+5.26%
1M Leistung:
+0.89%
6M Leistung:
-61.54%
1J Leistung:
-12.26%
1-Tages-Spanne:
$6.6201
$6.96
1-Wochen-Bereich:
$6.19
$6.96
52-Wochen-Spanne:
$5.54
$22.25
Optimizerx Corp Stock (OPRX) Company Profile
Firmenname
Optimizerx Corp
Sektor
Branche
Telefon
248-651-6558
Adresse
260 CHARLES STREET, WALTHAM, MI
Compare OPRX vs VEEV, TEM, BTSG, HQY, WAY
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OPRX
Optimizerx Corp
|
6.80 | 123.08M | 109.43M | 5.13M | 18.91M | 0.2606 |
VEEV
Veeva Systems Inc
|
174.64 | 28.42B | 3.20B | 908.91M | 1.39B | 5.4168 |
TEM
Tempus Ai Inc
|
47.30 | 8.47B | 1.27B | -245.03M | -245.36M | -1.4071 |
BTSG
Brightspring Health Services Inc
|
43.51 | 8.28B | 12.91B | 104.80M | 394.69M | 0.8769 |
HQY
Healthequity Inc
|
83.44 | 7.15B | 1.31B | 215.20M | 408.32M | 2.4627 |
WAY
Waystar Holding Corp
|
23.63 | 4.55B | 1.10B | 112.09M | 283.19M | 0.6096 |
Optimizerx Corp Stock (OPRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-08 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-12-20 | Eingeleitet | Stephens | Equal-Weight |
| 2024-07-25 | Fortgesetzt | B. Riley Securities | Buy |
| 2024-04-04 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-01-03 | Eingeleitet | Barclays | Equal Weight |
| 2023-02-02 | Fortgesetzt | B. Riley Securities | Buy |
| 2022-11-01 | Eingeleitet | Stifel | Buy |
| 2022-07-15 | Eingeleitet | SVB Leerink | Outperform |
| 2021-10-18 | Fortgesetzt | B. Riley Securities | Buy |
| 2021-04-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2019-01-03 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Optimizerx Corp Aktie (OPRX) Neueste Nachrichten
OptimizeRx (OPRX) soars 5.9%: Is further upside left in the stock? - MSN
Are Investors Undervaluing OptimizeRx (OPRX) Right Now? - qz.com
If You Invested $1,000 in Optimizerx Corp (OPRX) - Stock Titan
What Makes OptimizeRx Corp. (OPRX) a Strong Momentum Stock: Buy Now? - MSN
OptimizeRx (OPRX) price target decreased by 40.41% to 14.79 - MSN
New Top-Rated Stocks to Buy for April 1st - Bitget
OPRX Should I Buy - Intellectia AI
OptimizeRx (NASDAQ: OPRX) switches auditors from UHY LLP to Grant Thornton - stocktitan.net
OptimizeRx Corp. (NASDAQ:OPRX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - marketbeat.com
Vanguard disaggregates holdings; OPRX parent reports 0 shares (OPRX) - stocktitan.net
OPRX Technical Analysis & ETF Price Forecast - Intellectia AI
OptimizeRx (OPRX) Jumps 5.9%: Does the Stock Have More Room to Grow? - Bitget
Earnings call transcript: OptimizeRx Q4 2025 earnings beat forecasts, stock dips - Investing.com Australia
OPRX SEC FilingsOptimizerx Corp 10-K, 10-Q, 8-K Forms - Stock Titan
OptimizeRx (OPRX) Soars 5.9%: Is Further Upside Left in the Stock? - finance.yahoo.com
Best Value Stocks to Buy for March 24th - sharewise.com
OptimizeRx Corp. (OPRX) Surpasses Q2 Earnings and Revenue Estimates - MSN
Strength seen in OptimizeRx (OPRX): Can its 7.5% jump turn into more strength? - MSN
Guidance Update: Can OptimizeRx Corporation sustain earnings growthEntry Point & Fast Entry Momentum Alerts - baoquankhu1.vn
OPRX Technical Analysis & Stock Price Forecast - Intellectia AI
How The OptimizeRx (OPRX) Narrative Is Shifting As Guidance Resets And Valuation Expectations Reprice - Yahoo Finance
OptimizeRx Corp. (NASDAQ:OPRX) Short Interest Down 16.4% in February - MarketBeat
Is OptimizeRx (OPRX) Stock Undervalued Right Now? - Yahoo Finance
Best Value Stocks to Buy for March 16th - The Globe and Mail
Can OPRX's Patient Engagement Tools Win Amid Fierce Competition? - MSN
OptimizeRx Corp. (OPRX) Q4 earnings and revenues beat estimates - MSN
OptimizeRx (OPRX) outlines AI-driven pharma marketing strategy and key risks - Stock Titan
Should you sell your OptimizeRx stock? - Cantech Letter
OptimizeRx Corporation Common Stock OPRX ) Stock Price Today & Analysis - Gotrade
OptimizeRx Corporation (NASDAQ:OPRX) Q4 2025 Earnings Call Transcript - Insider Monkey
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
OptimizeRx (OPRX) Q4 Profitability Turn Challenges Skeptical Earnings Narratives - simplywall.st
OptimizeRx (NASDAQ:OPRX) Price Target Cut to $20.00 by Analysts at Lake Street Capital - MarketBeat
OptimizeRx (NASDAQ:OPRX) Price Target Cut to $18.00 by Analysts at Roth Mkm - MarketBeat
OptimizeRx Warns Of Volatility From 'Most Favored Nation' Pricing Uncertainty - Bitget
Assessing OptimizeRx: Insights From 4 Financial Analysts - Benzinga
B. Riley Financial Reaffirms Buy Rating for OptimizeRx (NASDAQ:OPRX) - MarketBeat
OptimizeRx (OPRX) Target Price Lowered by Stephens & Co. | OPRX Stock News - GuruFocus
Stephens Cuts OptimizeRx (NASDAQ:OPRX) Price Target to $10.00 - MarketBeat
OptimizeRx (NASDAQ:OPRX) Announces Quarterly Earnings Results - MarketBeat
Stephens cuts OptimizeRx stock price target on soft pharma budgets - Investing.com Nigeria
OptimizeRx Corporation Q4 2025 Earnings Call Summary - Yahoo Finance
OptimizeRx (OPRX) Q4 2025 Earnings Call Transcript - AOL.com
Stephens cuts OptimizeRx stock price target on soft pharma budgets By Investing.com - Investing.com UK
UPDATE – OptimizeRx Reports Strong Fourth Quarter and Full Year 2025 Financial Results - The Globe and Mail
OptimizeRx Corp (OPRX) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... - Yahoo Finance
Finanzdaten der Optimizerx Corp-Aktie (OPRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Optimizerx Corp-Aktie (OPRX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Stelmakh Edward | Chief Finance & Strat Officer |
Dec 19 '25 |
Sale |
13.51 |
1,388 |
18,752 |
126,830 |
| Silvestro Stephen L | Chief Executive Officer |
Dec 19 '25 |
Option Exercise |
0.00 |
6,546 |
0 |
195,462 |
| Odence-Ford Marion | Chief Legal & Admin Officer |
Dec 19 '25 |
Option Exercise |
0.00 |
3,928 |
0 |
94,526 |
| Besch Doug | Chief Product & Tech Officer |
Dec 19 '25 |
Option Exercise |
0.00 |
1,964 |
0 |
71,536 |
| Odence-Ford Marion | Chief Legal & Admin Officer |
Oct 03 '25 |
Option Exercise |
0.00 |
6,649 |
0 |
92,550 |
| Silvestro Stephen L | Chief Executive Officer |
Oct 03 '25 |
Option Exercise |
0.00 |
6,649 |
0 |
190,536 |
| Silvestro Stephen L | Chief Executive Officer |
Oct 03 '25 |
Sale |
18.75 |
1,620 |
30,375 |
188,916 |
| Stelmakh Edward | Chief Finance & Strat Officer |
Oct 03 '25 |
Option Exercise |
0.00 |
16,623 |
0 |
127,387 |
| Besch Doug | Chief Product & Tech Officer |
Oct 03 '25 |
Option Exercise |
0.00 |
3,325 |
0 |
70,555 |
| Spangler Patrick D | Director |
Aug 28 '25 |
Sale |
17.49 |
11,120 |
194,489 |
44,215 |
1.79%
1.97%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):